Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 7/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16124577 | 0.95 | CA12 (0.50) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL5265859 | 0.93 | NAAA (0.53) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL20557107 | 0.89 | KMT2A (0.43) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL12999572 | 0.85 | CA12 (0.51) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL3402001 | 0.85 | TDP1 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL14218312 | 0.85 | CA12 (0.47) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL27829380 | 0.85 | CA12 (0.47) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL15613905 | 0.84 | CA12 (0.54) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL28210577 | 0.84 | CA12 (0.43) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL28210578 | 0.84 | CA12 (0.43) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021122744-A1 | SYNTHESIS OF AMANIN AND ITS DERIVATIVES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127461-A1 | METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID | XW LABORATORIES LIMITED (CN) | 2021-06-24 | — | — | WO | disclosed |
| EP-3792250-A1 | SYNTHESIS OF ALPHA-AMANITIN AND ITS DERIVATIVES | Pure Bioorganics SIA (LV) | 2021-03-17 | — | — | EP | disclosed |
| WO-2021004973-A1 | SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES | PURE BIOORGANICS SIA (LV) | 2021-01-14 | — | — | WO | disclosed |
| CN-107406422-A | Pyrazole derivatives as sGC stimulants | 铁木医药有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-9782390-B2 | Amidine substituted β-lactam compounds, their preparation and use as antibacterial agents | AICURIS GMBH & CO. KG (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20170100379-A1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AICURIS GMBH & CO. KG (DE) | 2017-04-13 | — | — | US | disclosed |
| EP-3124114-A1 | TRANSESTERIFICATION REACTION BY MEANS OF IRON CATALYST | Kyushu University, National University Corporation (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-9556165-B2 | Amidine substituted β-lactam compounds, their preparation and use as antibacterial agents | AICURIS GMBH & CO. KG (DE) | 2017-01-31 | — | — | US | disclosed |
| EP-2806873-B1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AICURIS GMBH & CO KG (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-20150045340-A1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AICURIS GMBH & CO. KG (DE) | 2015-02-12 | — | — | US | disclosed |
| WO-2013110643-A1 | AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AICURIS GMBH & CO. KG (DE) | 2013-08-01 | — | — | WO | disclosed |
| EP-1650185-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE BETA-HYDROXY- ALPHA-AMINOCARBOXYLIC ACID DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012047617-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-7799941-B2 | Process for producing optically active β-hydroxy-α-aminocarboxylic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| CN-1038939-C | Peptide compounds and process for preparing same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-07-01 | — | — | CN | disclosed |
| CN-1060848-A | Peptide compounds, process for preparing same and pharmaceutical compositions containing same | FUJISAWA PHARMACEUTICAL CO (JP) | 1992-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170100379-A1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AAAS, MGAM, PAM | CA12 4178/4885CA1 4715/4885CA2 4576/4885 |
| US-20150045340-A1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AAAS, MGAM, PAM | CA12 4178/4885CA1 4715/4885CA2 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.